HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IBL-302

triple kinase inhibitor

Networked: 4 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	O'Neill, Michael: 4 articles (11/2021 - 01/2019)
2.	Blanco-Aparicio, Carmen: 3 articles (11/2021 - 01/2020)
3.	Martinez, Sonia: 3 articles (01/2020 - 01/2019)
4.	Pastor, Joaquin: 3 articles (01/2020 - 01/2019)
5.	Cunningham, Darren: 2 articles (11/2021 - 01/2020)
6.	Bexell, Daniel: 2 articles (01/2020 - 01/2019)
7.	Esfandyari, Javanshir: 2 articles (01/2020 - 01/2019)
8.	Garcia-Ruiz, Cristian: 2 articles (01/2020 - 01/2019)
9.	Hansson, Karin: 2 articles (01/2020 - 01/2019)
10.	Mohlin, Sofie: 2 articles (01/2020 - 01/2019)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2020 - "We thus believe that the novel PIM and PI3K/mTOR inhibitor, IBL-302, represents an exciting new potential treatment option for breast cancer, and that it should be considered for clinical investigation." 01/01/2020 - "We thus evaluated the preclinical activity of IBL-302, in a range of breast cancer models. " 01/01/2020 - "Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer." 11/11/2021 - "IBL-302, currently in late preclinical development (AUM302), has recently demonstrated efficacy in neuroblastoma and breast cancer xenografts. " 01/01/2020 - "The combination of trastuzumab and IBL-302 significantly increased the anti-proliferative effect in HER2+ breast cancer cell line, and matched trastuzumab-resistant line, relative to testing either drug alone. "
2.	Neuroblastoma 11/11/2021 - "IBL-302, currently in late preclinical development (AUM302), has recently demonstrated efficacy in neuroblastoma and breast cancer xenografts. " 01/01/2019 - "Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. " 01/09/2020 - "Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma." 01/01/2019 - "IBL-302 was more effective than single PI3K inhibition in vitro, and IBL-302 treatment of neuroblastoma patient-derived xenograft (PDX) cells induced apoptosis, differentiated tumor cells, and decreased N-Myc protein levels. " 01/01/2019 - "Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma."
3.	Neoplasms (Cancer) 01/01/2019 - "Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. " 01/09/2020 - "Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma." 01/01/2019 - "IBL-302 was more effective than single PI3K inhibition in vitro, and IBL-302 treatment of neuroblastoma patient-derived xenograft (PDX) cells induced apoptosis, differentiated tumor cells, and decreased N-Myc protein levels. " 01/01/2019 - "Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma." 01/01/2019 - "While IBL-302 treatment alone reduced tumor growth in vivo, combination therapy with low-dose cisplatin inhibited neuroblastoma PDX growth. "

Related Drugs and Biologics

1.	Lapatinib (GW572016)
2.	Trastuzumab (Herceptin)
3.	Phosphotransferases (Kinase)
4.	Cisplatin (Platino)
5.	N-Myc Proto-Oncogene Protein

Related Therapies and Procedures

1.	Therapeutics